Rallybio Phase 2 trial of RLYB212 begins to tackle FNAIT in high-risk pregnancies
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company known for advancing innovative therapies for rare diseases, has commenced its Phase 2 clinical trial for RLYB212. ... Read More
OncoVerity accelerates AML treatment with Series A extension
OncoVerity, a leader in integrating bioinformatics with oncology drug development, has closed a Series A extension financing round, bolstered by its key investors, argenx and ... Read More
BirchBioMed reports breakthrough phase 2 trial results for FS2 in treating keloid scars
BirchBioMed, a Canadian clinical-stage immunology company, has unveiled promising results from a phase 2 trial of FS2, its pioneering antifibrotic therapy designed to treat keloid ... Read More
Dr. Reddy’s reports success in Sputnik V phase 2 trial, paving the way for phase 3 in India
Dr. Reddy’s Laboratories has announced a major milestone in the development of Sputnik V, the Russian Covid-19 vaccine, following its successful phase 2 clinical trial ... Read More
Xeris Pharmaceuticals begins Phase 2 trial for glucagon in Type 1 diabetes patients
Xeris Pharmaceuticals, a specialty pharmaceutical company based in Chicago, has announced the commencement of dosing in its phase 2 clinical trial. The trial aims to ... Read More
TWi Biotechnology begins Phase 2 trial for AC-203 in epidermolysis bullosa patients
TWi Biotechnology, a Taiwanese biopharmaceutical company, has initiated the enrollment of patients in a pivotal Phase 2 clinical trial evaluating its investigational drug, AC-203, for ... Read More
GNI Group to halt enrolment in Phase 2 liver fibrosis trial following positive results
Japanese biotech company GNI Group has announced it will cease enrolment of new patients in its Phase 2 liver fibrosis trial for the drug candidate ... Read More